PWPS
HRTX icon

Pinnacle Wealth Planning Services’s Heron Therapeutics HRTX Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$142 Hold
178
– – ﹤0.01% 2708
2025
Q4 		$231 Buy
+178
New +$220 ﹤0.01% 2706

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Pinnacle Wealth Planning Services's HRTX Position: Q1 2026 in Review

Pinnacle Wealth Planning Services held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 178 shares worth $142. The position accounts for ﹤0.01% of the portfolio, ranked #2708.

Pinnacle Wealth Planning Services first reported a position in HRTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $231 in Q4 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Pinnacle Wealth Planning Services held 178 shares of Heron Therapeutics worth $142 as of Q1 2026.
  • Pinnacle Wealth Planning Services left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q1 2026, its #2708 holding.
  • Pinnacle Wealth Planning Services first reported a position in Heron Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Pinnacle Wealth Planning Services's Heron Therapeutics position peaked at $231 in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q1 2026, filed 11 May 2026.